Prenatal Dexamethasone Treatment for Classic 21-hydroxylase Deficiency in Europe

Objective: To assess the current medical practice in Europe regarding prenatal dexamethasone (Pdex) treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.

Design And Methods: A questionnaire was designed and distributed, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 30 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN.

Results: Pdex treatment is currently provided by 36% of the surveyed centres. The treatment is initiated by different specialties, that is paediatricians, endocrinologists, gynaecologists or geneticists. Regarding the starting point of Pdex, 23% stated to initiate therapy at 4-5 weeks postconception (wpc), 31% at 6 wpc and 46 % as early as pregnancy is confirmed and before 7 wpc at the latest. A dose of 20 µg/kg/day is used. Dose distribution among the centres varies from once to thrice daily. Prenatal diagnostics for treated cases are conducted in 72% of the responding centres. Cases treated per country and year vary between 0.5 and 8.25. Registries for long-term follow-up are only available at 46% of the centres that are using Pdex treatment. National registries are only available in Sweden and France.

Conclusions: This study reveals a high international variability and discrepancy in the use of Pdex treatment across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidence-based guidelines on prenatal diagnostics, treatment and follow-up of pregnancies at risk for CAH.

Citing Articles

Long-Read Sequencing Identifying the Genetic Complexity of Congenital Adrenal Hyperplasia in the Pedigree.

Chen X, Zhao J, Li D, Xi N, Yi D, Yan M Mol Genet Genomic Med. 2024; 12(11):e70029.

PMID: 39575462 PMC: 11582476. DOI: 10.1002/mgg3.70029.

Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.

Neocleous V, Fanis P, Toumba M, Skordis N, Phylactou L Orphanet J Rare Dis. 2024; 19(1):167.

PMID: 38637882 PMC: 11027394. DOI: 10.1186/s13023-024-03171-4.

Dexamethasone affects human fetal adrenal steroidogenesis and subsequent ACTH response in an culture model.

Melau C, Gayete Mor B, Lundgaard Riis M, Nielsen J, Dreisler E, Aaboe K Front Endocrinol (Lausanne). 2023; 14:1114211.

PMID: 37484942 PMC: 10358843. DOI: 10.3389/fendo.2023.1114211.

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia.

Vant Westeinde A, Karlsson L, Messina V, Wallensteen L, Brosamle M, Dal Maso G Endocr Connect. 2023; 12(4).

PMID: 36752813 PMC: 10083667. DOI: 10.1530/EC-22-0400.

Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia.

Cera G, Locantore P, Novizio R, Maggio E, Ramunno V, Corsello A J Clin Med. 2022; 11(20).

PMID: 36294476 PMC: 9605322. DOI: 10.3390/jcm11206156.

References

Vant Westeinde A, Karlsson L, Nordenstrom A, Padilla N, Lajic S . First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age. J Clin Endocrinol Metab. 2020; 105(8). PMC: 7304558. DOI: 10.1210/clinem/dgaa340. View

New M, Carlson A, Obeid J, Marshall I, Cabrera M, Goseco A . Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab. 2001; 86(12):5651-7. DOI: 10.1210/jcem.86.12.8072. View

Wallensteen L, Zimmermann M, Thomsen Sandberg M, Gezelius A, Nordenstrom A, Hirvikoski T . Sex-Dimorphic Effects of Prenatal Treatment With Dexamethasone. J Clin Endocrinol Metab. 2016; 101(10):3838-3846. DOI: 10.1210/jc.2016-1543. View

Reisch N, Willige M, Kohn D, Schwarz H, Allolio B, Reincke M . Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012; 167(1):35-42. DOI: 10.1530/EJE-12-0161. View

Meyer-Bahlburg H, Khuri J, Reyes-Portillo J, Ehrhardt A, New M . Stigma Associated with Classical Congenital Adrenal Hyperplasia in Women's Sexual Lives. Arch Sex Behav. 2017; 47(4):943-951. DOI: 10.1007/s10508-017-1003-8. View

Riveline J, Baz B, Nguewa J, Vidal-Trecan T, Ibrahim F, Boudou P . Exposure to Glucocorticoids in the First Part of Fetal Life is Associated with Insulin Secretory Defect in Adult Humans. J Clin Endocrinol Metab. 2019; 105(3). DOI: 10.1210/clinem/dgz145. View

Wallensteen L, Karlsson L, Messina V, Gezelius A, Thomsen Sandberg M, Nordenstrom A . Evaluation of behavioral problems after prenatal dexamethasone treatment in Swedish children and adolescents at risk of congenital adrenal hyperplasia. Horm Behav. 2018; 98:219-224. DOI: 10.1016/j.yhbeh.2017.11.004. View

Tardy-Guidollet V, Menassa R, Costa J, David M, Bouvattier-Morel C, Baumann C . New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002-2011). J Clin Endocrinol Metab. 2014; 99(4):1180-8. DOI: 10.1210/jc.2013-2895. View

Hirvikoski T, Nordenstrom A, Lindholm T, Lindblad F, Ritzen E, Lajic S . Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?. Eur J Endocrinol. 2008; 159(3):309-16. DOI: 10.1530/EJE-08-0280. View

10.

Hirvikoski T, Nordenstrom A, Wedell A, Ritzen M, Lajic S . Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. J Clin Endocrinol Metab. 2012; 97(6):1881-3. DOI: 10.1210/jc.2012-1222. View

11.

Alfirevic Z, Navaratnam K, Mujezinovic F . Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev. 2017; 9:CD003252. PMC: 6483702. DOI: 10.1002/14651858.CD003252.pub2. View

12.

Miller W . Fetal endocrine therapy for congenital adrenal hyperplasia should not be done. Best Pract Res Clin Endocrinol Metab. 2015; 29(3):469-83. DOI: 10.1016/j.beem.2015.01.005. View

13.

Forest M, BETUEL H, David M . Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res. 1989; 15(1-2):277-301. DOI: 10.1080/07435808909039101. View

14.

Nordenstrom A, Frisen L, Falhammar H, Filipsson H, Holmdahl G, Janson P . Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: clinical perspective and the patients' perception. J Clin Endocrinol Metab. 2010; 95(8):3633-40. DOI: 10.1210/jc.2009-2639. View

15.

Elsayed S, Badawy H, Khater D, Abdelfattah M, Omar M . Congenital adrenal hyperplasia: Does repair after two years of age have a worse outcome?. J Pediatr Urol. 2020; 16(4):424.e1-424.e6. DOI: 10.1016/j.jpurol.2020.06.010. View

16.

Therrell B . Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001; 30(1):15-30. DOI: 10.1016/s0889-8529(08)70017-3. View

17.

Speiser P, Azziz R, Baskin L, Ghizzoni L, Hensle T, Merke D . Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(9):4133-60. PMC: 2936060. DOI: 10.1210/jc.2009-2631. View

18.

White P . Ontogeny of adrenal steroid biosynthesis: why girls will be girls. J Clin Invest. 2006; 116(4):872-4. PMC: 1421368. DOI: 10.1172/JCI28296. View

19.

Simpson J, Rechitsky S . Prenatal genetic testing and treatment for congenital adrenal hyperplasia. Fertil Steril. 2019; 111(1):21-23. DOI: 10.1016/j.fertnstert.2018.11.041. View

20.

Mercado A, Wilson R, Cheng K, Wei J, New M . Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1995; 80(7):2014-20. DOI: 10.1210/jcem.80.7.7608248. View